FOXO4-DRI
Senolytic PeptideAlso known as: FOXO4-p53 disruptor · Senolytic FOXO4
A retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells, triggering their selective apoptosis. The first peptide-based senolytic.
Typical Dose
1–5 mg, 3x/week (investigational human protocols)
Route
Subcutaneous injection
Cycle
2–4 weeks; then extended break (senolysis is not expected to need continuous treatment)
Half-life
Unknown in humans (D-amino acid peptide — longer than L-amino acid analogs)
Storage
Lyophilized: 2–8°C. Reconstituted: 2–8°C, use within 14 days.
Overview
FOXO4-DRI is a D-amino acid retro-inverso peptide based on a segment of FOXO4 that interacts with p53 in senescent cells to prevent apoptosis. Senescent cells — damaged cells that have stopped dividing but resist dying — accumulate with aging & drive chronic inflammation, tissue dysfunction, & age-related disease.
By disrupting the FOXO4-p53 interaction, FOXO4-DRI selectively triggers apoptosis in senescent cells while sparing normal cells (which do not have this aberrant FOXO4-p53 interaction). Mouse studies showed remarkable restoration of physical fitness, hair regrowth, & improved organ function within weeks of treatment.
FOXO4-DRI is purely a research compound at this stage. It has a very high molecular weight (~5168 Da) & relatively complex synthesis. Human data consists only of case reports.
Quick Start Guide
FOXO4-DRI is an advanced research compound with no established human dosing protocol.
Mouse studies used 1.5 mg/kg IP 3x/week for 10 days. Some human protocols extrapolate to 1–5 mg SubQ 3x/week for 2–4 weeks.
This should be considered investigational — consult relevant literature before use.
Research Indications
Cellular senescence clearance (senolyis)
Research OnlyMouse studies: 3x/week for 10 days cleared hepatic, renal, & peripheral senescent cells. Restored physical fitness, hair, & organ function in aged mice.
Research Protocols
Senolytic cycle (investigational)
10 days to 4 weeks; then extended off periodDose
1–5 mg
Frequency
3x/week SubQ
Route
SubQ abdomen
Side Effects & Safety
Common
- Unknown in humans. Mouse studies showed generally good tolerability.
Uncommon
- Theoretical concern: apoptosis of any normally-senescent cells involved in physiological processes
When to Stop
- Any unexpected systemic effects
- Signs of allergic reaction
How to Reconstitute
Reconstitute with 1 mL BAC water per 5 mg vial. Swirl gently. Refrigerate.
Dosing math: 1 mL BAC water per 5 mg = 5000 mcg/mL. For 5 mg: 1.0 mL.
Quality Indicators
Good — use as normal
- Clear solution — large peptide may take longer to dissolve
Acceptable
- Faint opalescence clearing within a few minutes of gentle swirling
Discard immediately
- Persistent cloudiness
- Visible aggregation
What to Expect
During cycle (10 days – 4 weeks)
Senescent cell clearance occurs over the course of the cycle. Effects are not experientially apparent; outcomes are structural.
Weeks 4–12 post-cycle
If senolysis occurred, regenerative response in cleared tissues expected. Mouse data shows tissue restoration & improved physical performance in this window.
Community Insights
Self-reported. Reflects user experience, not clinical outcomes.
Research References
Cell · 2017
Landmark Nature study demonstrating FOXO4-DRI selectively kills senescent cells & restores tissue & physical function in aged mice.
doi:10.1016/j.cell.2017.02.031 →Verify what you have
Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.
Submit a sample